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cytokines and hormones are essential mediators in the regulation of anti­
microbial peptide and protein (amP) levels during host defense responses. In this 
issue, Büchau et al. identify and characterize B­cell leukemia­3 as an important 
modulator of amP expression during the innate immune response in keratino­
cytes as well as in the chronic inflammatory skin disorder atopic dermatitis.
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antimicrobial peptides and proteins
Humans are constantly exposed to 
infection by pathogenic microorgan-
isms and agents. In most cases, we are 
able to resist infection with the help of 
immunity, which is composed of two 
major defenses: innate or nonspecific 
immunity, which acts immediately 
after infection, and adaptive or specif-
ic immunity, which is more powerful 
and pathogen specific. When skin is 
breached by an injury, pathogens that 
invade the host are initially eliminated 
by mobilized cellular host defenses, 
including neutrophils, macrophages, 
mast cells, eosinophils, and natural 
killer cells. These cells express a vari-
ety of recognition receptors, such as 
toll-like receptors (TLRs), which are 
activated in part by microbial patho-
gens. TLRs then promote the release of 
mediators, including those that initi-
ate the complement cascade, cytok-
ines, chemokines, superoxides, nitric 
oxides, and antimicrobial peptides 
and proteins.
Antimicrobial peptides (AMPs) and 
proteins (including defensins, cathe-
licidin, histatins, human β-defensin 
(HBD), cathepsin G, high-mobility 
group box-1 (HMGB1), and lacto-
ferrin; Kolls et al., 2008)—which are 
produced by different inflammatory 
and noninflammatory cells, including 
keratinocytes—have various mecha-
nisms of action and are divided into 
different groups. Many of the anti-
microbial peptides are produced 
constitutively and stored in secretory 
granules, and others are induced 
by proinflam matory stimuli such as 
IL-1, tumor necrosis factor (TNF), and 
lipopolysaccharide (Kolls et al., 2008). 
With the exception of HBD1, most 
AMPs are undetectable in skin under 
basal conditions but are induced after 
injury or inflammatory stimuli.
AMPs are believed to act by depo-
larizing and/or piercing bacter-
ial cell membranes. Besides killing 
gram-positive and -negative bacteria, 
AMPs can kill fungi and certain viruses. 
In addition to their antimicrobial 
activity, AMPs can regulate innate 
immune responses by inducing 
chemokines and cytokines. Cytokine 
signaling leads to the recruitment of 
inflammatory cells, including mac-
rophages and neutrophils, which fur-
ther increase antimicrobial protein 
responses (Kolls et al., 2008). However, 
negative feedback regulation by some 
AMPs has previously been reported 
to diminish inflammation. Cytokines 
and hormones such as vitamin D are 
well-known mediators in AMP regula-
tion in keratinocytes. Specifically, the 
vitamin D response element was iden-
tified in the promoter region of the 
human cathelicidin gene (Schauber 
et al., 2007). Stimulation of kerati-
nocytes with the active metabolite 
1,25-(OH)2 vitamin D3 (1,25D3) 
increased transcription and activation 
of cathelicidin, leading to antimicrobial 
activity against Staphylococcus aureus 
(Schauber et al., 2008).
B­cell leukemia­3 and keratinocytes
A variety of microbial components 
activate the transcription factor nucle-
ar factor-κB (NF-κB), which is impor-
tant in the activation of host immune 
responses. The receptor-mediated 
signaling pathway leading to NF-κB 
activation by the microbial compo-
nents is mainly through TLR ligands 
and proinflammatory cytokines such 
as TNF and IL-1. In nonstimulated 
cells, NF-κB is located in the cyto-
plasm; upon activation it translocates 
into the nucleus, where it activates 
the transcription of target genes. Five 
members of the NF-κB protein family 
have been discovered: p50, p52, p65, 
RelB, and c-Rel. B-cell leukemia-3 
(Bcl-3), a member of the inhibitor 
NF-κB family, will interact only with 
p50 and p52 (Massoumi and Paus, 
2007). The role of Bcl-3 during NF-κB 
signaling is complicated and varies 
depending on the manner of activa-
tion and the cell type that responds. 
In keratinocytes, activation of Bcl-3 by 
12-O-tetradecanoylphorbol-13 ace tate 
or UV radiation caused rapid trans-
location of Bcl-3 to the nucleus and 
recruitment of p50/p52 to target genes 
for the transcription of genes such as 
cyclin D1 (Massoumi et al., 2006). 
In addition, sustained Bcl-3 nuclear 
translocation led to the development 
of skin papillomas (Massoumi et al., 
2006) or squamous-cell carcinomas 
(Budunova et al., 1999), by augmen-
tation of p50/p52-related NF-κB 
binding in mouse keratinocytes. In 
other systems, Bcl-3 can act as a tran-
scription repressor by binding to p50 
homodimers. For example, the repres-
sor function of Bcl-3 was recent-
ly demonstrated in TLR signaling, 
where the tolerance and suppression 
were dependent on the coordinated 
action of a p50–Bcl-3 complex. In the 
absence of this complex, loading of 
NF-κB subunits on target promoters, 
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which is critical for appropriate gene 
expression, was disrupted, leading to 
aberrant expression of inflammatory 
genes. This suggested that inflamma-
tory responses can be controlled effec-
tively by targeting the NF-κB p50 and 
Bcl-3 pathway (Carmody et al., 2007).
Even though the means by which 
AMP expression is regulated by dif-
ferent cytokines during infection and 
inflammation has been established, 
it is not known which targets can 
respond to the related cytokine pro-
file and thereby affect AMP expres-
sion directly. Büchau et al. (2009, this 
issue) identify Bcl-3 as an important 
modulator for expression of AMPs dur-
ing innate responses by keratinocytes. 
Indeed, two potent mediators of the 
Th2-driven innate response, IL-4 and 
IL-13, induced Bcl-3 expression. This, 
in turn, led to the downregulation 
of HBD3 expression. Further, when 
Bcl-3 expression in keratinocytes was 
silenced by siRNA, the downregulato-
ry effect of IL-4 on that expression was 
reversed. In contrast, TNF-α-mediated 
upregulation of HBD3 via Th1 cyto-
kines IL-6 and IL-8 was reduced in the 
presence of Bcl-3 siRNA (Figure 1). 
Together, these results highlight Bcl-3 
as a common effector molecule for 
both Th1 and Th2 cytokines in regu-
lating AMP levels during the innate 
responses by keratinocytes.
atopic dermatitis
Atopic dermatitis (AD) is a chronic 
inflammatory skin disorder that causes 
patients to have frequent bacterial 
and viral skin infections, which can 
eventually advance to superinfection. 
Although the cause of AD is not entire-
ly clear, its etiology involves a com-
plex interplay among environmental 
triggers and genetic factors, including 
altered innate and adaptive immune 
responses. Further, AD patients’ defec-
tive innate immune systems may allow 
bacterial infections to persist despite 
therapy (Wollenberg and Bieber, 2000; 
Leung and Bieber, 2003). The patients’ 
susceptibility to pathogens and infec-
tions has been related to diminished 
recruitment of innate immune cells 
to the skin, epithelial barrier disrup-
tion, TLR2 defects, and a reduction in 
AMPs (Dokmeci and Herrick, 2008). 
The reduction in AMP levels in these 
patients was correlated with the over-
expression of Th2 cytokines such as 
IL-4 and IL-13. Because IL-4 induces 
IgE production in B cells, an eventual 
suppression of anti-infectious immune 
responses will occur via the reduction 
of AMPs and inhibition of Th1 immu-
nity. Other studies demonstrate that 
IL-8, which is a potent chemokine 
that attracts polymorphonuclear leu-
kocytes (PMNs) into the skin where 
they phagocytize and kill bacteria, 
upregulates the expression of HBD2 
and HBD3. This picture became even 
more certain when it was shown that 
TNF-α-induced IL-8 expression was 
inhibited by IL-4, demonstrating that 
interplay between cytokine profiles 
can regulate the expression of AMPs 
(Bieber, 2008).
The report by Büchau et al. (2009) 
is the first study to connect the func-
tion of Bcl-3 to AD and explain how 
Bcl-3 can decrease the expression 
of AMPs mediated by the related 
cytokine profile observed in AD 
patients. Initial observations indicate 
that Bcl-3 is overexpressed at both the 
mRNA and protein levels in lesional 
skin from AD patients compared with 
normal skin. Because Th2 cytokines 
such as IL-4 and IL-13 are overex-
pressed in AD patients, normal human 
keratino cytes were exposed to these 
cyto kines. Interestingly, a combination 
of IL-4 and IL-13 enhanced the levels 
of Bcl-3 in keratinocytes in the cyto-
plasm, suggesting that elevated Bcl-3 
expression in AD is directly controlled 
by the levels of IL-4 and IL-13 (Büchau 
et al., 2009).
Earlier studies documented the role 
of vitamin D in the expression of the 
cathelicidin gene via stimulation of 
keratinocytes with the active metab-
olite 1,25D3, in which an increase 
in cathelicidin levels was observed 
(Schauber et al., 2007). To deter-
mine whether vitamin D can regulate 
Bcl-3 levels, AD patients were treated 
Figure 1. Downregulation of human β­defensin­3 (HBD3) levels by B­cell leukemia­3 (Bcl­3). 
Increased expression of Bcl-3 in keratinocytes by IL-4 and IL-13 causes downregulation of HBD3 levels. 
The effect of TNF-α-mediated production of IL-6 and IL-8, as well as HBD3 expression levels, was 
blocked in the presence of Bcl-3. TNFR, tumor necrosis factor receptor.
|Blocking Bcl-3 downstream signaling is a potential therapy 
in AD.
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with orally administered vitamin D, 
resulting in downregulation of Bcl-3 
expression in lesional AD skin in a 
majority of subjects (Büchau et al., 
2009). To further confirm that Bcl-3 
signaling is important in the regula-
tion of cathelicidin levels, keratino-
cytes were treated with siRNA against 
Bcl-3 before stimulation with 1,25D3. 
1,25D3 strongly induced cathelici-
din gene expression; this effect was 
further enhanced when the levels of 
Bcl-3 were reduced (in the presence 
of Bcl-3-siRNA; Figure 2). To deter-
mine whether the Bcl-3–p50 complex 
is important for this pathway, Büchau 
et al. (2009) used a blocking pep-
tide against p50 and found an effect 
similar to that of Bcl-3 silencing. This 
indicated that the regulation of cathe-
licidin expression involves blocking of 
p50 subunits by Bcl-3 in the promoter 
region of human cathelicidin.
Future directions
The elegant study performed by 
Büchau et al. (2009) can be seen as 
a major step toward clinical trials for 
AD treatment, but there are still ques-
tions that must be addressed. Is the 
effect of vitamin D or IL-4/IL-13 on 
human Bcl-3 levels direct or indirect? 
Can the Bcl-3–p52 complex share the 
same target gene and repressor activ-
ity in AD as Bcl-3–p50? What percent-
age of nuclear localized Bcl-3 in AD 
and keratinocytes is stimulated by Th2 
cytokines? Are Bcl-3 levels depen-
dent entirely on promoter activation 
or can posttranslational modification 
of Bcl-3, including ubiquitination, 
play a role in AD? Is the level of CYLD 
altered in these patients?
It has previously been shown that 
inactive Bcl-3 is localized mainly in 
the cytoplasm, whereas the active form 
of Bcl-3 translocates into the nucleus 
for binding to the promoter of differ-
ent genes. Furthermore, Bcl-3 levels 
can be regulated by polyubiquitina-
tion. Therefore, the fate of Bcl-3 is 
decided by the type of ubiquitin chains 
attached. Bcl-3 has been shown to be a 
substrate for both lysine 63 and lysine 
48 ubiquitin chains. Lysine 63 mediates 
nuclear localization of Bcl-3, whereas 
lysine 48 directs Bcl-3 to the protea-
some for degradation. An increase in 
Bcl-3–lysine 63 ubiquitination, which 
might be detected in AD patients, can 
mediate stabilization as well as sus-
tained downstream activity/signaling of 
Bcl-3. A loss of the CYLD gene, which 
blocks activity of Bcl-3 signaling, could 
be another possible explanation for the 
role of Bcl-3 in AD patients.
Taking together these findings, 
Bcl-3, which was previously shown to 
act as an oncogene in skin-mediated 
tumorigenesis and melanoma, seems to 
have an essential role in AD; therefore, 
blocking Bcl-3 downstream signaling 
in keratinocytes may be a potential 
therapeutic target in treating AD.
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Figure 2. Downregulation of cathelicidin levels by B­cell leukemia­3 (Bcl­3). Tumor necrosis factor-α 
(TNF-α) can induce cathelicidin only in the presence of 1,25-dihydroxyvitamin D3 (1,25D3). Increased 
expression of cathelicidin in keratinocytes by 1,25D3 and TNF-α is inhibited in the presence of Bcl-3. 
TNFR, tumor necrosis factor receptor.
